Home » Topics » Disease categories and therapies » Cardiovascular

Cardiovascular
RSS

Anti-E-selectin antisense compound from Isis inhibits mRNA splicing

Dec. 6, 1996

Cytel announces plans for Cylexin at investors conference

Dec. 5, 1996

New endothelin receptor modulators reported by Texas Biotechnology

Dec. 4, 1996

Once-daily antihypertensive combination cleared for marketing in Canada

Dec. 3, 1996

New hope for heart failure patients

Dec. 3, 1996

Therapeutically active NPY analogues reported by Salk Institute

Dec. 2, 1996

Takeda discloses natural ET receptor antagonist

Nov. 29, 1996

NEP inhibitors claimed by Santen

Nov. 28, 1996

XOMA receives U.S. patents covering BPI-related products

Nov. 27, 1996

Japanese researchers describe orally active antihypertensive agents

Nov. 27, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 14, 2025.
European VCs optimistic for med-tech exit opportunities in 2025
BioWorld MedTech
To say that European investors are optimistic about the outlook for the med-tech sector in 2025 is an understatement. A couple of companies are already listed on...
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for February 14, 2025
European VCs bullish on med-tech investments in 2025
BioWorld MedTech
European companies looking for capital should find the fundraising environment more favorable in 2025. Private med-tech financings in January totaled about $2...
Kura/Kyowa Kirin’s ziftomenib hits phase II endpoints in AML
BioWorld
Kura Oncology Inc. and Kyowa Kirin Co. Ltd.’s selective oral menin inhibitor, ziftomenib, met the primary endpoints in the phase II registrational Komet-001 trial...